An observational study in Hospital-acquired Pneumonia and Antibiotic Resistant Infection, sponsored by Ruijin Hospital. Not yet recruiting. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2023-09-08.
Sponsored by Ruijin Hospital · Observational
The goal of this prospective and observatory study is to learn about the pathogen, clinical manifestations, prognosis, treatment and antibiotic resistance of bacteria in hospital-acquired pneumonia patients in China.
The main purposes of this study are:
2,044 studies on the registry are indexed under Pneumonia; 283 are open to participants now.
This study's planned enrollment of 4,000 is above the median of 203 across 688 observational studies indexed under Pneumonia.
Browse Pneumonia studies →Ruijin Hospital is the lead sponsor of 635 studies on the registry; 359 are open to participants now.
Counted across the registry records on this site, refreshed daily.
hospital-acquired pneumonia adult patients with qualified evidence of responsible pathogen in China
Exclusion Criteria:
patients still survive at 28 days
Other: prognosis status
patients die within 28 days
Other: prognosis status
observatory; patients will be divided into survival group and mortality group according to their prognosis at day 28
mortality at day 28
prognosis
Time frame: 28 days after enrollment
clinical characteristics
symptoms, physical examinations, comorbidity, laboratory tests, imaging findings and treatment
Time frame: 0 day, 3 days, 7days, 14 days and 28 days after enrollment
pathogen
molecular characteristics of responsible pathogen; antibiotic resistance of bacteria
Time frame: 0 day, 3 days, 7days, 14 days and 28 days after enrollment
No study locations are listed for this record.
This study is not yet recruiting, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ruijin Hospital